Synaptiflora Israeli Company

Synaptiflora addresses the high failure rates, lengthy timelines, and rising costs in drug development, where 90% of drugs fail and average development costs exceed $2.5 billion. Our product is an AI-powered platform that leverages microbiome, genomic, and clinical data to provide pharmaceutical companies with precise, disease-specific tools, initially targeting colorectal cancer and expanding into neurology and immunology.